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Abstract
Background: Persistence is a key factor for long-term blood pressure control, which is of high
prognostic importance for patients at increased cardiovascular risk. Here we present the results of
a post-marketing survey including 4769 hypertensive patients treated with irbesartan in 886 general
practices in Switzerland. The goal of this survey was to evaluate the tolerance and the blood
pressure lowering effect of irbesartan as well as the factors affecting persistence in a large
unselected population.
Methods:  Prospective observational survey conducted in general practices in all regions of
Switzerland. Previously untreated and uncontrolled pre-treated patients were started with a daily
dose of 150 mg irbesartan and followed up to 6 months.
Results: After an observation time slightly exceeding 4 months, the average reduction in systolic
and diastolic blood pressure was 20 (95% confidence interval (CI) -19.6 to -20.7 mmHg) and 12
mmHg (95% CI -11.4 to -12.1 mmHg), respectively. At this time, 26% of patients had a blood
pressure < 140/90 mmHg and 60% had a diastolic blood pressure < 90 mmHg. The drug was well
tolerated with an incidence of adverse events (dizziness, headaches,...) of 8.0%. In this survey more
than 80% of patients were still on irbesartan at 4 month. The most important factors predictive of
persistence were the tolerability profile and the ability to achieve a blood pressure target ≤  140/90
mmHg before visit 2. Patients who switched from a fixed combination treatment tended to
discontinue irbesartan more often whereas those who abandoned the previous treatment because
of cough (a class side effect of ACE-Inhibitors) were more persistent with irbesartan.
Conclusion: The results of this survey confirm that irbesartan is effective, well tolerated and well
accepted by patients, as indicated by the good persistence. This post-marketing survey also
emphasizes the importance of the tolerability profile and of achieving an early control of blood
pressure as positive predictors of persistence.
Background
Angiotensin II receptor antagonists (AIIRA) have demon-
strated excellent efficacy in patients with hypertension
[1,2], heart failure [1,2], diabetes [3], diabetic nephropa-
thy [4-6], and recently in post-myocardial infarction
patients [7]. Such promising results allowed the US Joint
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National Committee on hypertension in their seventh
report (JNC-7) and the European Society of Hypertension
(ESH-ESC) in the 2003 guidelines to integrate this class of
agents in the management of hypertension and to pro-
pose AIIRAs as an alternative treatment to ACE-inhibitors
for most of the above-mentioned high-risk conditions
[8,9].
However, the main message of the published guidelines
remains that a normalization of arterial blood pressure in
hypertensive patients is the key objective to the preven-
tion of cardiovascular events, especially in high-risk cate-
gories, where stricter therapeutic targets and aggressive
strategies to reach them have been proposed. Yet, achiev-
ing normalization of blood pressure (BP) remains a diffi-
cult task, or, in the words of the JNC-7 report [8]: "The
most effective therapy prescribed by the most careful cli-
nician will control hypertension only if the patient is
motivated to take the prescribed medication and to estab-
lish and maintain a health-promoting lifestyle." In indus-
trialized countries, the success rates in controlling blood
pressure range from below 10% to 30% of the treated
population, depending mainly on the definition of the
therapeutic targets [10-14]. The JNC-7 report estimates
that 34% of hypertensive patients in the USA manage to
maintain a BP below 140/90 mmHg [8].
The inadequate persistence with therapy, i.e. the frequent
switch or discontinuation of the prescribed therapy has
been recognized as a frequent cause of treatment failure
[15]. Persistence is a good general indicator of the satisfac-
tion with the treatment of both patients and physicians.
Among classes, a British comparative study showed ACE-
inhibitors as the best and diuretics as the poorest persist-
ence builders [15]. A large Canadian cohort study based
on pharmacy prescriptions confirmed these results [16].
Recently, the first population-based studies including
AIIRAs revealed that patients persist more with AIIRAs
than with all other antihypertensive drugs after 6 months
up to 3 years [17,18]. A cohort study with 2416 newly
diagnosed hypertensive patients showed that the AIIRA
irbesartan induced significantly more persistence than
other drug classes and even than other AIIRAs [19]. This
improved persistence has been attributed in part to the
efficacy of the compounds and mainly to the low, pla-
cebo-like side effects profile [20-22]. Placebo-like tolera-
bility has indeed been confirmed at all clinically relevant
dosages of irbesartan [23].
The aim of this open prospective observational survey
with 4769 hypertensive patients treated in general prac-
tices in Switzerland, was to evaluate the persistence with
irbesartan in real-life settings over a period of about one
year and to investigate factors affecting either positively or
negatively the persistence. In addition, the tolerability
profile and the effect of irbesartan on BP control were
assessed.
Methods
Design of the investigation
This prospective observational survey was conducted in
general practices in all regions of Switzerland from Octo-
ber 1997 to March 1999 i.e. shortly after the launch of
irbesartan in the country. The general practitioners (GPs)
were asked to document their daily routine in the treat-
ment of hypertensive patients with irbesartan; 1390 phy-
sicians were contacted, 1045 included patients and 886
documented the treatment. They were recruited by the
field forces of the sponsors of the study i.e. BMS and
Sanofi-Synthelabo Switzerland. GPs filled in a baseline
visit (Visit 1) form for every treated patient, and could
report up to five follow up visits in the following 3–6
months (End Form). They were asked to document two
arterial blood pressure measurements at every visit and to
report concomitant antihypertensive medication and
adverse events, as well as changes or discontinuation of
treatment. At the end of the observation period, GPs
reported if their patients were continuing the treatment
with irbesartan, alone or in combination with other anti-
hypertensive drugs. About 1 year after baseline, patients
with ongoing treatment with irbesartan received a Com-
pliance Form Patient, where they were asked how irbe-
sartan was tolerated (very well, well, fairly well, poorly)
and how many times weekly they took irbesartan in the
preceding 3–4 weeks; a further question was how many
tablets (all drugs) were taken daily. Their GPs received a
Compliance Form MD, to report the last blood pressure
measurement and if and when the patient had discontin-
ued the treatment. The various forms were designed by
external consultants. The data were collected by mail
using self-addressed envelopes and processed by the con-
sultants. Queries for incomplete forms were done by the
sponsor representatives. No standard validated question-
naire was used. In Switzerland, this type of survey does
not need to be submitted to an ethical committee.
Patient selection
All patients with newly diagnosed hypertension, or with
treated hypertension requiring a change in medication
according to the GP, were considered for the survey. No
standardized definition was used but physicians consid-
ered a BP >140/90 mmHg as hypertension. There were
neither demographic nor clinical exclusion criteria. The
only condition to participate was that patients should not
have been pre-treated with irbesartan. Treatment was
started with irbesartan 150 qd. Thereafter, physicians were
free to change the antihypertensive therapy at any time
during the follow-up based on their individual therapeu-
tic goals (usually <140/90 mmHg).BMC Cardiovascular Disorders 2005, 5:13 http://www.biomedcentral.com/1471-2261/5/13
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Statistical analysis
Values are presented as mean +/- sd. The statistical signif-
icance of between-group differences was computed using
the 2-sided Chi-square test, the Mann-Whitney-U test or
ANOVA methods as appropriate. For multivariate correla-
tions, a logistic regression analysis with a dichotomous
dependent variable was used (e.g. therapy discontinua-
tion: yes = 1; no = 0). To support the results of the logistic
regression models, Cox regression models with cumula-
tive survival functions were further computed.
Results
Characteristics of the database
As shown in Figure 1, 5452 patients were enrolled by
1045 GPs, and 886 of those returned the therapy docu-
mentation (End Form) of 4769 patients (87.5%). This lat-
ter sample was taken to analyze the safety data and is
referred to as AE-Sample (Tolerability Events). For the
evaluation of the effect on BP control, all cases with at
least one follow-up value were taken into account. 130
cases of the AE-Sample had no follow-up values; the
remaining 4639 subjects (97.3% of the AE-Sample) are
referred to as the Efficacy Sample. At the end of the treat-
ment observation period, after an average of slightly more
than 4 months (133 ± 75 days, mean ± SD), GPs reported
that 3829 patients (82.5% of the Efficacy sample) contin-
ued the treatment with irbesartan. This is referred to as the
Sample with Ongoing Therapy. A total of 1419 Compli-
ance Forms MD (37.1% of the sample with ongoing ther-
apy) and 928 Compliance Forms Patient (24.2%) were
returned after on average more than 13 months from
baseline (402 ± 105 days). Due to lack of completeness,
some forms had to be excluded from the analysis, giving a
total of 1186 valid Compliance Forms MD (31.0%) and
853 cases with both usable Compliance Form MD and
Patient (22.2%).
Table 1 summarizes the baseline demographic and clini-
cal data for both the previously untreated and the pre-
treated patients. Almost two thirds of the patients
(61,5%) entered the study receiving another therapy for
high blood pressure. The most frequent reasons why GPs
changed pre-treatment to introduce irbesartan were insuf-
ficient efficacy of the previous therapy (64.6%), cough
(22.5%) and adverse events other than cough (16.6%).
The multivariate analysis of factors correlated to pre-treat-
ment shows that patients who switched to irbesartan from
other antihypertensive drugs were older, prevalently
female and from the German part of Switzerland (p <
0.001). They had significantly more risk factors, associ-
ated clinical conditions (p < 0.0001) and target organ
damages than naïve patients (p = 0.0013). More pre-
treated patients received a polytherapy regimen during the
post-marketing surveillance (p < 0.0001).
Effect on blood pressure
More that 90% of the Efficacy Sample patients received
irbesartan 150 mg qd, as a monotherapy or in combina-
tion with other antihypertensives. 69% of the Efficacy
Sample patients received a constant monotherapy and
5.6% a constant polytherapy. In the Efficacy Sample, the
mean reduction of systolic blood pressure (SBP) from
baseline to the last visit was 20.2 ± 19.5 mmHg (p <
0.001). For the diastolic blood pressure (DBP), the mean
reduction was 11.7 ± 11.3 mmHg (p < 0.001). Figure 2a
shows the differences between naïve and pre-treated
patients. Despite previous treatment, the pre-treated
group had clearly inadequate mean baseline values of SBP
and DBP (163.5 and 96.3 mmHg, respectively) justifying
a change in therapy. Naïve patients achieved a signifi-
cantly greater reduction of both SBP and DBP than pre-
treated ones. At the last visit, the pre-treated group showed
higher SBP and similar DBP values in comparison to naïve
patients.
Since GPs did not receive specific instructions about ther-
apeutic goals in this survey, various therapeutic targets
were used to evaluate the success in controlling blood
pressure (Figure 2b). As shown in the figure, one third of
the patients had normalized their BP (<140/90 mmHg)
and two-thirds had a diastolic BP below 90 mmHg. The
Sample with Ongoing Therapy, as reasonably expected,
appeared slightly more successful than the Efficacy Sam-
ple in achieving the various targets (Figure 2b).
Tolerability profile
Adverse events were reported for 383 patients (8.0% of
the AE-Sample), more often by older patients (>65 years:
10.2%; 55–65 years: 7.8%; = 55 years: 5.5%; p < 0.001)
and by pre-treated patients (9.6% vs. 5.5% naïve; p <
0.001). Yet, in the majority of patients (90.7%), irbesartan
was well tolerated according to GPs. Tolerance was
reported as poor only for 131 patients (2.7%). Adverse
events led to discontinuation of irbesartan in 343 cases
(7.4%). The most frequent side effects are listed in Table
2, where they are compared with their occurrence listed in
the Swiss prescribing information [24]. Serious adverse
events, leading to death, disability, life-threatening condi-
tions or hospitalization, were reported in 74 patients
(1,3% of AE-sample), but GPs described a possible or
probable connection with trial medication only in 8 cases.
Very good or good tolerance was reported by 824 patients
in the Compliance Form Patient (96.6% of the total), all
subgroups scoring above 90%.
Persistence
3829 patients out of 4639 continued the treatment with
irbesartan after the last visit (on average, more than 4
months from the start). The main reasons for discontinu-
ation of the remaining 810 patients were the occurrence ofBMC Cardiovascular Disorders 2005, 5:13 http://www.biomedcentral.com/1471-2261/5/13
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adverse events and an insufficient efficacy (figure 3). In a
logistic regression model, the factors that correlated more
strongly with ongoing therapy were a reported good toler-
ance and reaching the a blood pressure ≤  140/90 mmHg.
Interestingly, pre-treated patients discontinued irbesartan
significantly more often when the previous therapy was a
fixed combination of antihypertensive agents, but not if
they had stopped the pre-treatment because of cough,
which on the contrary increased the probability of therapy
continuation. Treatment modifications also affected per-
sistence. Thus, if the dose of irbesartan was increased or
another antihypertensive agent was added at the first fol-
low up visit (Visit 2), patients had better chances to stay
on therapy whereas, if treatment was modified after visit
2, this was associated with more discontinuations. In the
former situation 9.5% of patients persisted on therapy. In
contrast, if further changes in drug therapy were necessary
on visit 3 because of insufficient BP control 35.9% of drug
Patient population and available data Figure 1
Patient population and available data. Summary of the analysis patient populations of this investigation and of the data 
available for analysis.
End form returned
AE sample
N=4769
(87.5% of included patients)
No end form returned
N=683
(12.5% of included patients)
Included patients
N=5452
Follow-up values
Efficacy Sample
N=4639
(97.3% of the AE-Sample)
No follow-up value
N=130
(2.7% of AE sample)
After about 4 months:
Irbesartan treatment continued
Sample with Ongoing Therapy
N=3829
(82.5% of Efficacy Sample)
Discontinuation of treatment
N=810
(17.5% of Efficacy Sample)
After about 13 months:
Valid Compliance form Patient
N= 853 (22.3% of Sample with Ongoing Therapy)
Valid Compliance Form MD
N=1186 (31.0% of Sample with Ongoing Thearpy.)
No compliance form
MD / Patient returned
(N=1790)BMC Cardiovascular Disorders 2005, 5:13 http://www.biomedcentral.com/1471-2261/5/13
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Table 1: Baseline demographic and clinical data: Efficacy Sample.
Naïve patients Pre-treated Total
Total 1785 (38.5%) 2854 (61.5%) 4639
Gender (f/m) 882/903 1605/1249 2487/2152
Mean age ± SD 57.9 ± 12.7 63.6 ± 12.3 61.4 ± 12.8
Baseline SBP (Mean ± SD) 168.8 ± 17.8 163.5 ± 19.1 165.5 ± 18.8
Baseline DBP (Mean ± SD) 101.2 ± 8.6 96.3 ± 10.4 98.2 ± 10.0
Diabetes 165 (9.2%) 492 (17.2%) 657 (14.2%)
ISH 79 (4.4%) 408 (14.3%) 487 (10.5%)
WHO-risk
Low (<15%) 37 (2.1%) 101 (3.5%) 138 (3.0%)
Medium (15–20%) 837 (46.9%) 1190 (41.7%) 2027 (43.7%)
High (20–30%) 274 (15.4%) 526 (18.4%) 800 (17.2%)
Very high (>30%) 637 (35.7%) 1037 (36.3%) 1674 (36.1%)
For detailed explanation of WHO-risk and region categories see results. ISH = isolated systolic hypertension (defined as ≥  140 mmHg systolic and 
< 90 mmHg diastolic blood pressure).
a. Evolution of blood pressure during observation period (~4 months): Efficacy Sample Figure 2
a. Evolution of blood pressure during observation period (~4 months): Efficacy Sample. Baseline SBP (systolic 
blood pressure): previously untreated patients 168.8 mmHg, pre-treated 163.5 mmHg (*p < 0.0001); SBP at last visit: previ-
ously untreated 142.8 mmHg, pre-treated 146.9 mmHg (p < 0.0001). Baseline DBP (diastolic blood pressure): previously 
untreated patients 101.2 mmHg, pre-treated 96.3 mmHg (*p < 0.0001); DBP at last visit: previously untreated 85.9 mmHg, pre-
treated 86.8 mmHg (p = 0.004). b. Reaching of therapeutic targets: Efficacy Sample. Response to treatment is defined 
as reaching DBP < 90 mmHg or a reduction of DBP = 10 mmHg. In real-life practice, a satisfactory objective is also the normal-
ization of DBP (< 90 mmHg). Target = 140/90 mmHg was introduced because of digit preference of study GPs (see results).
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therapies were discontinued. The survival analysis (Cox
regression) generally confirmed the statistically significant
relationships with persistence found in the logistic regres-
sion models (Figure 4). An effect detected only by the Cox
regression was the positive correlation between persist-
ence and number of risk factors for cardiovascular dis-
eases at baseline (RR = 0.74 for the discontinuation; p =
0.0001). Diabetes did not appear to influence persistence.
In both multivariate analyses, the presence of a family his-
tory of hypertension or cardiovascular diseases reduced
the chances of persistence.
Perception of compliance
Patients with ongoing therapy at last visit were asked in
the Compliance Form Patient to indicate how many irbe-
sartan tablets they took per week during the preceding 3–
4 weeks. Since after about one year only 853 patients
returned the form, we have to assume a sampling bias.
Nevertheless, some within-group differences are worth
mentioning. 777 patients (91.1%) who returned the
Compliance Form Patient reported an irbesartan intake of
6–7 times per week, i.e. more than 80% of the prescribed
doses. All subgroups scored around 90% (Figure 5), but
females reported a better compliance than males (92.9%
vs. 89.0%; p = 0.021). Patients with isolated systolic
hypertension appear to adhere better to therapy than
other hypertensives (97.2% vs. 90.2%; p = 0.032), while
patients with a low risk for cardiovascular events showed
a lower compliance (84%, n.s.). Compliance Forms MD
reported an overall ongoing treatment rate with irbesartan
of 88.0% (1044 patients), and a slightly higher rate for
pre-treated patients (90.4%, n = 728).
Discussion
Taken together, the data of this postmarketing survey con-
firm that irbesartan is a well tolerated and effective
antihypertensive agent when used in a real life setting at
the dose of 150 mg qd. More interestingly, our data pro-
vide further insights on factors affecting either positively
or negatively the persistence with antihypertensive treat-
ment. In particular, our observations point out the impor-
tance of a good tolerability profile and of achieving a
rapid control of blood pressure in enhancing persistence
whereas late changes in treatment and addition of irbe-
sartan in patients already treated with a fixed-dose combi-
nation appears to be factors promoting a lower
persistence.
Prospective observational surveys are not specifically
designed to evaluate the antihypertensive efficacy of a new
agent since there is generally no control group and the
treatment schedule is not standardized. Moreover, there
may be a selection bias since the inclusion of patients was
not randomised. Nevertheless, this type of survey may
provide some valid information on the antihypertensive
effect that may be obtained in real life conditions i.e. out-
side the rigorous context of a clinical trial and the rather
large number of patients included certainly limit the effect
of a systematic selection bias. In the present case most
patients were treated with a 150 mg irbesartan tablet per
day because this was the dose recommended at the time
the survey was conducted, i.e. soon after the launch of
irbesartan in Switzerland. All patient subgroups, but in
particular naïve patients, responded positively to the treat-
ment. In fact, in the group of patients with follow-up val-
ues and after a mean observation time of 4 months, the
average reductions in blood pressure were of comparable
Table 2: Most reported adverse events in the AE-Sample (n = 
4769) compared to the Swiss prescribing guidance
AE-Sample Swiss prescribing guidance
Total 383 (8.0%)
Dizziness 65 (1.4%) >1%
Nausea 53 (1.1%) >1%
Headache 43 (0.9%) >1%
Dyspepsia 24 (0.5%) 0.5–1%
Diarrhea 18 (0.4%) 0.5–1%
Palpitation 17 (0.4%) Not mentioned
Cough 15 (0.3%) 0.5–1%
Fatigue 15 (0.3%) >1%
Vomiting 11 (0.2%) >1%
Tachycardia 10 (0.2%) 0.5–1%
Ongoing treatment and discontinuation reasons Figure 3
Ongoing treatment and discontinuation reasons: Effi-
cacy Sample. (n = 4639)Other reasons included: patient 
moved, blood pressure normalized, break off attempt, con-
current disease, effect too strong, lost to follow up and oth-
ers. Multiple answers were possible.
0%
20%
40%
60%
80%
100%
Ongoing therapy Discontinuations
Other reasons (4.1%)
Insufficient adherence (3.5%)
Adverse events (6.2%)
Insufficient efficacy (6.3%)
% of patientsBMC Cardiovascular Disorders 2005, 5:13 http://www.biomedcentral.com/1471-2261/5/13
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magnitude that those obtained in clinical trials and in
other post-marketing surveys [25-27]. Such a substantial
reduction could be achieved in spite of the fact that irbe-
sartan 150 mg represents the minimal recommended
daily dosage nowadays.
Of note, no blood pressure target was pre-defined in our
program. Moreover, one should consider that the
reported blood pressure values show a clear digit prefer-
ence for figures ending with a 0 or a 5. This reflects the
tendency of the GPs to round blood pressure values,
explainable by the wide use of sphygmomanometers.
Therefore, the effect on blood pressure was assessed using
different criteria. With the generally accepted targets of
<140/90 mmHg or a diastolic BP below 90 mmHg,
respectively 26 % and 60% of patients were controlled
with 150 mg irbesartan qd. In a more recent survey, in
which physicians had the opportunity to use the higher
dose of 300 mg or the combinations of irbesartan 150 or
300 mg with hydrochlorothiazide 12.5 mg, the percent-
age of patients with a blood pressure below 140/90
mmHg increases to more than 60% [28]. Looking at sub-
populations, older patients and pre-treated patients had
more problems in reaching the therapeutic target chosen
for analysis (≤  140/90 mmHg). The same was true for
patients with more cardiovascular risk factors, but not for
people with associated clinical conditions – the highest
risk factor according to the WHO 1999 guidelines, JNC-7
Mean (line) and 95% confidence interval (box) for the odds ratio (OR) of the main variables correlating significantly with ongo- ing treatment or discontinuation in a logistic regression model; Efficacy Sample Figure 4
Mean (line) and 95% confidence interval (box) for the odds ratio (OR) of the main variables correlating significantly with ongo-
ing treatment or discontinuation in a logistic regression model; Efficacy Sample. For detailed explanations see results.
0.01 0.1 1 10 100
Tolerance
Reaching BP <=140/90 mmHg
Change of medication at visit 2
Cough during previous treatment
SBP at visit 1
Adverse events
Reduction of irbesartan
dosage or stop of another drug
Family history
Increase of irbesartan dosage or
addition of new drug
Pre-treatment: fixed combination
DBP at visit 1
OR
persistence
more likely
discontinuation
more likely
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Reduction of irbesartan
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discontinuation
more likely
variables correlating
with treatment persistenceBMC Cardiovascular Disorders 2005, 5:13 http://www.biomedcentral.com/1471-2261/5/13
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Self-reported compliance according to the patient for selected patient subgroups Figure 5
Self-reported compliance according to the patient for selected patient subgroups. Good compliance with treatment after 1 
year; Compliance Form Patient (n = 853). Good compliance is defined as >80% adherence to the prescribed therapeutic regimen. In 
this case it means irbesartan intake on 6 or 7 days a week, as reported by the patients. Risk = WHO risk categories; ISH = isolated systo-
lic hypertension; constant mono-and polytherapy; on & off = on and off treatment breaks; * = p < 0.05 compared to the rest of the 
patients.
75% 80% 85% 90% 95% 100%
Total
Female
Male
<55 y.
55-65 y.
>65 y.
Low risk
Medium risk
High risk
Very high risk
Pre-treated
Naïve
Diabetic
Non-diabetic
ISH
No ISH
Constant mono
Constant poly
*
*
*BMC Cardiovascular Disorders 2005, 5:13 http://www.biomedcentral.com/1471-2261/5/13
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and ESH-ESC 2003 guidelines – who, on the contrary,
reached the target more easily [8,9,29]. This observation
further emphasize the known difficulty to achieve a good
control of systolic blood pressure particularly in elderly
patients with isolated systolic hypertension.
In post-marketing surveys in real life settings, the evalua-
tion of safety is of great importance. More than 90% of
patients tolerated the treatment well or very well accord-
ing to their GPs and adverse events were reported by only
8% of them. Serious adverse events possibly or probably
related to irbesartan occurred in less than ten cases. The
patients with more risk factors tolerated irbesartan equally
well, despite taking significantly more drugs. The most
frequent adverse events were dizziness, nausea, headache,
dyspepsia and diarrhea, and occurred at the rate described
in the Swiss prescribing information. These data therefore
confirm the excellent tolerability profile of angiotensin II
receptor antagonists reported in clinical trials [30].
The main observation of the present survey is the assess-
ment of the factors determining long-term persistence
with the irbesartan treatment in our population. Out of
the 4639 patients with complete follow-up data, 82.5%
continued to take irbesartan for more than 4 months.
When evaluating factors affecting persistence some inter-
esting observations were made. The first and expected
ones are that a good tolerability profile and the achieve-
ment of a rapid blood pressure control are positively
associated with the long-term persistence with therapy.
This finding would therefore encourage the use of well-
tolerated antihypertensive drugs such as angiotensin II
receptor antagonists at high doses in order to obtain a
rapid control of blood pressure. It may also favor the use
of fixed dose combinations as first line treatment since
these combinations are associated with a low side-effect
profile and an improved efficacy [31].
A consistent majority of the study population (61.5%)
entered the trial after a failed experience with other anti-
hypertensive drugs. Irbesartan proved to be the drug
inducing more persistence in a comparative study with
newly-diagnosed patients [19]; therefore, it was also inter-
esting to appraise the persistence rate in pre-treated
patients. To our surprise, patients who switched from a
fixed combination treatment tended to discontinue irbe-
sartan more often. On the contrary, patients who aban-
doned the previous treatment because of cough (a class
side effect of ACE-Inhibitors), tended to stick more to
irbesartan. Moreover, late changes in treatment schedule
had a negative impact on persistence whereas early
changes in treatment had a rather favorable impact on
persistence. These negative influences on persistence are
probably linked to the increased complexity of the treat-
ment schedule which is known to impair compliance as
well as persistence. Indeed, several previous studies have
demonstrated that drug adherence decreases in propor-
tion with the complexity of the drug regimen [32,33].
In this survey, an attempt was made to obtain information
on drug adherence using simplified questionnaires
addressed to the patients and physicians. Unfortunately,
only a small proportion of these questionnaires were
filled by the participants. There is therefore a high proba-
bility of bias towards highly compliant patients. Moreo-
ver, questionnaires are known to overestimate drug
adherence. Hence it is not surprising that good compli-
ance with the dosing schedule was reported by more than
90% of the patients after about one year treatment, mean-
ing that this fraction of the patients reported to have taken
irbesartan at least 6 times a week in the preceding 3–4
weeks. Yet, the results of more than 1000 questionnaires
confirm previous observations such as the lower compli-
ance in men and the absence of effect of age. Indeed,
Degoulet at al have also reported thatmale sex is a variable
significantly associated with an increased dropout rate in
hypertensive patients attending a hypertension clinic [34].
Of interest is the observation that patients with a low car-
diovascular risk appear to have a lower compliance
whereas those presenting with an isolated systolic hyper-
tension have a higher compliance. These findings may be
related to the patients' perception of their disease and
their degree of concern. Thus, patients with a low cardio-
vascular risk may be less motivated to take their medica-
tions whereas patients with high systolic blood pressure
may be particularly concerned by their hypertension. In
line with this finding, we have found recently that epilep-
tic patients well controlled under treatment are less com-
pliant than those experiencing repeated seizures despite
treatment [35].
In conclusion, this survey confirms that irbesartan is a safe
and effective antihypertensive drug in clinical practice. A
high persistence with irbesartan was found in this pro-
gram which is likely related to the consistent reductions in
blood pressure and the good tolerability profile. This
post-marketing survey has also tend to confirm in a large
population of patients that achieving an early control of
blood pressure may be a positive predictor of persistence.
Based on this observation one could encourage physicians
to start the antihypertensive therapy more aggressively
using higher doses of well tolerated drugs such as
angiotensin II receptor antagonists or fixed low-dose
combinations in order to improve blood pressure control
as well as long-term persistence.
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